PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
Publisher: Datamonitor Healthcare
Published: 27 July 2020
Number of pages:43
PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29.
Overview – UCB will experience impressive growth of its core portfolio of CNS and I&I products through 2021, but patent expiries will cause growth to slow over the long term.
Key themes –  UCB will see solid near-term revenue growth due to its strong immunology and neurology assets  UCB saw several positive readouts from the Phase III program for bimekizumab in late 2019 that bode well for future uptake of the product  Growth from pipeline products – bimekizumab, zilucoplan, and rozanolixizumab – and recently launched Nayzilam and Evenity will see UCB increase revenues over the forecast period  UCB has several sizable brands with upcoming loss of exclusivity: Vimpat in 2022, Cimzia in 2024, and Briviact in 2026.
Model updates (27 July 2020)
Bimekizumab forecast adjusted higher due to recent clinical trial results showing superiority to current standard-of-care
Zilucoplan forecast added after closing of Ra Pharma acquisition
Padsevonil forecast removed after UCB formally suspends program.
Model updates (20 May 2020)
Padsevonil forecast lowered due to disappointing results from the Phase IIb ARISE trial.
Model updates (20 February 2020)
Cimzia forecast adjusted higher
Evenity forecast adjusted in 5EU and RoW to reflect approval and launch in first half of 2020
Bimekizumab forecast adjusted higher due to strong results from three Phase III trials – BE VIVID, BE READY, and BE SURE.
Model updates (25 July 2019)
Cimzia forecast adjusted higher due to growth in new patient populations, such as women of childbearing age and people living with psoriasis
Vimpat forecast adjusted higher due to market share gains in all regions
Briviact forecast adjusted higher due to continued growth in all regions
Evenity launch in Europe delayed due to negative CHMP opinion and UCB appeal
Nayzilam forecast added
Padsevonil forecast added
Rozanolixizumab forecast added.
Table of Contents
Key Drug & Company Information
Prescription Pharmaceuticals Sales Outlook
Branded Drug Outlook
Launch Profile Outlook
Therapy Area Outlook
Regional Sales Outlook
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726